Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew D Marsden

Showing results (31-40 of 42) with videos related to

Pageof 5
Sort By:
Plos One|September 17, 2015
Disruption of Type I Interferon Induction by HIV Infection of T CellsDavid Jesse Sanchez, Daniel Miranda, Matthew D Marsden, et al.
ACS Nano|July 26, 2014
Bioengineered vaults: self-assembling protein shell-lipophilic core nanoparticles for drug deliveryDaniel C Buehler, Matthew D Marsden, Sean Shen, et al.
The Journal of Clinical Investigation|February 11, 2025
Rapamycin enhances CAR-T control of HIV replication and reservoir elimination in vivoWenli Mu, Shallu Tomer, Jeffrey Harding, et al.
Cell Reports. Medicine|December 30, 2020
Tracking HIV Rebound following Latency Reversal Using Barcoded HIVMatthew D Marsden, Tian-Hao Zhang, Yushen Du, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 7, 2020
Prodrugs of PKC modulators show enhanced HIV latency reversal and an expanded therapeutic windowJack L Sloane, Nancy L Benner, Katherine N Keenan, et al.
Biorxiv : the Preprint Server for Biology|February 6, 2026
Leveraging HIV-Specific CAR T Cells and Rapamycin Treatment in "Kick-and-Kill" HIV Cure ApproachesNishad S Maggirwar, José A Morán, Wenli Mu, et al.
Plos Pathogens|September 22, 2017
In vivo activation of latent HIV with a synthetic bryostatin analog effects both latent cell "kick" and "kill" in strategy for virus eradicationMatthew D Marsden, Brian A Loy, Xiaomeng Wu, et al.
Immunity|January 1, 2013
Interferon-inducible cholesterol-25-hydroxylase broadly inhibits viral entry by production of 25-hydroxycholesterolSu-Yang Liu, Roghiyh Aliyari, Kelechi Chikere, et al.
Virology|May 26, 2018
Characterization of designed, synthetically accessible bryostatin analog HIV latency reversing agentsMatthew D Marsden, Xiaomeng Wu, Sara M Navab, et al.
Journal of Virology|March 8, 2019
Humanized Mouse Model of HIV-1 Latency with Enrichment of Latent Virus in PD-1<sup>+</sup> and TIGIT<sup>+</sup> CD4 T CellsGeorge N Llewellyn, Eduardo Seclén, Stephen Wietgrefe, et al.
Pageof 5

Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
Plos One|September 17, 2015
Disruption of Type I Interferon Induction by HIV Infection of T CellsDavid Jesse Sanchez, Daniel Miranda, Matthew D Marsden, et al.
ACS Nano|July 26, 2014
Bioengineered vaults: self-assembling protein shell-lipophilic core nanoparticles for drug deliveryDaniel C Buehler, Matthew D Marsden, Sean Shen, et al.
The Journal of Clinical Investigation|February 11, 2025
Rapamycin enhances CAR-T control of HIV replication and reservoir elimination in vivoWenli Mu, Shallu Tomer, Jeffrey Harding, et al.
Cell Reports. Medicine|December 30, 2020
Tracking HIV Rebound following Latency Reversal Using Barcoded HIVMatthew D Marsden, Tian-Hao Zhang, Yushen Du, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 7, 2020
Prodrugs of PKC modulators show enhanced HIV latency reversal and an expanded therapeutic windowJack L Sloane, Nancy L Benner, Katherine N Keenan, et al.
Biorxiv : the Preprint Server for Biology|February 6, 2026
Leveraging HIV-Specific CAR T Cells and Rapamycin Treatment in "Kick-and-Kill" HIV Cure ApproachesNishad S Maggirwar, José A Morán, Wenli Mu, et al.
Plos Pathogens|September 22, 2017
In vivo activation of latent HIV with a synthetic bryostatin analog effects both latent cell "kick" and "kill" in strategy for virus eradicationMatthew D Marsden, Brian A Loy, Xiaomeng Wu, et al.
Immunity|January 1, 2013
Interferon-inducible cholesterol-25-hydroxylase broadly inhibits viral entry by production of 25-hydroxycholesterolSu-Yang Liu, Roghiyh Aliyari, Kelechi Chikere, et al.
Virology|May 26, 2018
Characterization of designed, synthetically accessible bryostatin analog HIV latency reversing agentsMatthew D Marsden, Xiaomeng Wu, Sara M Navab, et al.
Journal of Virology|March 8, 2019
Humanized Mouse Model of HIV-1 Latency with Enrichment of Latent Virus in PD-1<sup>+</sup> and TIGIT<sup>+</sup> CD4 T CellsGeorge N Llewellyn, Eduardo Seclén, Stephen Wietgrefe, et al.
Pageof 5